Circio, a pre-clinical biotech company that is listed on the Oslo stock exchange, has developed a form of RNA technology that, if successful, could make cell and gene therapy much safer, more effective and more economic, and therefore available to a wide population. HBI sat down with Lubor Gaal, the company’s CFO, at Jefferies’ Global Healthcare Conference in London this week, to understand a bit more about the technology and what the company needs to get to market.
Search over 7,000 articles
